Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012
BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4656 (Published 23 July 2013) Cite this as: BMJ 2013;347:f4656
- Keith B Hoffman, vice president, scientific affairs1,
- Andrea Demakas, analyst1,
- Colin B Erdman, technical lead1,
- Mo Dimbil, senior analyst1,
- P Murali Doraiswamy, professor2
- 1AdverseEvents, 230 Center Street, Healdsburg, CA 95448, USA
- 2Departments of Psychiatry and Medicine, DUMC-3018, Duke University Medical Center, Durham, NC 27710, USA
- keith{at}adverseevents.com
Publications from Roche and a case-control study suggest that there is no evidence, or plausible mechanism of action, to link neuropsychiatric adverse events to Tamiflu (oseltamivir).1 2 Cochrane Collaborators, the BMJ, and others, however, contend that many of Roche’s data remain unavailable.3
We examined neuropsychiatric adverse events associated with oseltamivir in the US FDA’s Adverse Event Reporting System (FAERS) from October 1999 to August 2012 by using a data mining platform (RxFilterTM; www.AdverseEvents.com4) to generate case report …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.